F_RD

C Number:	C20203
Lock Date:	11/14/2006
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	2.1.0

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF GREEN TEA EXTRACT

MALE RATS

Organ	Morphology
Adrenal Cortex	Vacuolization Cytoplasmic
Liver	Infiltration Cellular Mononuclear Cell
Lung	Hemorrhage
Lymph Node, Mandibular	Hyperplasia
	Hyperplasia Lymphoid
Lymph Node, Mesenteric	Infiltration Cellular Histiocyte
Nose: Lamina Propria	Pigmentation Histiocyte
Nose: Nasopharyngeal Duct	Degeneration
	Inflammation
Nose: Nerve	Atrophy
Nose: Olfactory Epithelium	Atrophy
	Metaplasia
	Necrosis
	Pigmentation
Nose: Olfactory Epithelium, Glands	Hyperplasia
Nose: Respiratory Epithelium	Hyperplasia
Testes: Seminiferous Tubule	Degeneration
Thymus	Atrophy

FEMALE RATS

Organ	Morphology
Liver	Mitosis
	Pigmentation
Liver: Bile Duct	Hyperplasia
Liver: Oval Cell	Hyperplasia
Liver: Periportal	Hypertrophy
Lymph Node, Mandibular	Hyperplasia
	Hyperplasia Lymphoid
Lymph Node, Mesenteric	Infiltration Cellular Histiocyte
Nose	Inflammation
Nose: Lamina Propria	Pigmentation Histiocyte
Nose: Nerve	Atrophy

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF GREEN TEA EXTRACT

Nose: Olfactory Epithelium	Atrophy
	Metaplasia
	Pigmentation
Nose: Olfactory Epithelium, Glands	Hyperplasia
Thymus	Atrophy

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Adrenal Cortex						
Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	3/10 (30%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	3/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	30%	0%	0%	0%	0%	0%
TERMINAL (d)	3/10 (30%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.095N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.095N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.095N
COCH-ARM / FISHERS	P=0.059N	(e)	(e)	(e)	(e)	P=0.105N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.025N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Heart **Cardiomyopathy**						
LESION RATES						
OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	8/10 (80%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	8/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	80%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	8/10 (80%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.377N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Kidney **Mineralization**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.227
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.227
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.227
COCH-ARM / FISHERS	P=0.132	(e)	(e)	(e)	(e)	P=0.237
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.066

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Kidney						
Nephropathy						
LESION RATES						
OVERALL (a)	8/10 (80%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	5/10 (50%)
POLY-3 RATE (b)	8/10.00	0/0.00	0/0.00	0/0.00	0/0.00	5/10.00
POLY-3 PERCENT (g)	80%	0%	0%	0%	0%	50%
TERMINAL (d)	8/10 (80%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	5/10 (50%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.174N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.174N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.174N
COCH-ARM / FISHERS	P=0.121N	(e)	(e)	(e)	(e)	P=0.175N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.079N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver						
Hepatodiaphragmatic Nodule						
LESION RATES						
OVERALL (a)	1/10 (10%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	1/10.00	0/10.00	0/10.00	1/10.00	2/10.00
POLY-3 PERCENT (g)	10%	10%	0%	0%	10%	20%
TERMINAL (d)	1/10 (10%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	93 (T)	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.176	P=0.760	P=0.500N	P=0.500N	P=0.760	P=0.500
POLY 1.5	P=0.176	P=0.760	P=0.500N	P=0.500N	P=0.760	P=0.500
POLY 6	P=0.176	P=0.760	P=0.500N	P=0.500N	P=0.760	P=0.500
COCH-ARM / FISHERS	P=0.171	P=0.763N	P=0.500N	P=0.500N	P=0.763N	P=0.500
MAX-ISO-POLY-3	P=0.116	P=1.000	P=0.158N	P=0.158N	P=1.000	P=0.274

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver						
Infiltration Cellular Mononuclear Cell						
LESION RATES						
OVERALL (a)	7/10 (70%)	9/10 (90%)	7/10 (70%)	5/10 (50%)	8/10 (80%)	4/10 (40%)
POLY-3 RATE (b)	7/10.00	9/10.00	7/10.00	5/10.00	8/10.00	4/10.00
POLY-3 PERCENT (g)	70%	90%	70%	50%	80%	40%
TERMINAL (d)	7/10 (70%)	9/10 (90%)	7/10 (70%)	5/10 (50%)	8/10 (80%)	4/10 (40%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.054N	P=0.292	P=0.678	P=0.329N	P=0.500	P=0.186N
POLY 1.5	P=0.054N	P=0.292	P=0.678	P=0.329N	P=0.500	P=0.186N
POLY 6	P=0.054N	P=0.292	P=0.678	P=0.329N	P=0.500	P=0.186N
COCH-ARM / FISHERS	P=0.057N	P=0.291	P=0.686N	P=0.325N	P=0.500	P=0.185N
MAX-ISO-POLY-3	P=0.027N*	P=0.136	P=1.000	P=0.188N	P=0.310	P=0.089N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver						
Mitosis						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver Pigmentation						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver: Bile Duct Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	1/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	10%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	93 (T)	---	---	---	---
STATISTICAL TESTS						
POLY 3	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
POLY 1.5	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
POLY 6	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.193N	P=0.158	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver: Oval Cell Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver: Periportal Hypertrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lung						
Hemorrhage						
LESION RATES						
OVERALL (a)	6/10 (60%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	6/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	60%	0%	0%	0%	0%	0%
TERMINAL (d)	6/10 (60%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P<0.001N**
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P<0.001N**
POLY 6	(e)	(e)	(e)	(e)	(e)	P<0.001N**
COCH-ARM / FISHERS	P=0.004N**	(e)	(e)	(e)	(e)	P=0.005N**
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lung **Inflammation**						
LESION RATES						
OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	7/10 (70%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	7/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	70%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	7/10 (70%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.292N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.292N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.292N
COCH-ARM / FISHERS	P=0.201N	(e)	(e)	(e)	(e)	P=0.291N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.136N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lymph Node, Mandibular						
Hyperplasia						
LESION RATES						
OVERALL (a)	5/10 (50%)	10/10 (100%)	7/10 (70%)	9/10 (90%)	8/10 (80%)	8/10 (80%)
POLY-3 RATE (b)	5/10.00	10/10.00	7/10.00	9/10.00	8/10.00	8/10.00
POLY-3 PERCENT (g)	50%	100%	70%	90%	80%	80%
TERMINAL (d)	5/10 (50%)	10/10 (100%)	7/10 (70%)	9/10 (90%)	8/10 (80%)	8/10 (80%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.381	P=0.008**	P=0.329	P=0.061	P=0.174	P=0.174
POLY 1.5	P=0.381	P=0.008**	P=0.329	P=0.061	P=0.174	P=0.174
POLY 6	P=0.381	P=0.008**	P=0.329	P=0.061	P=0.174	P=0.174
COCH-ARM / FISHERS	P=0.384	P=0.016*	P=0.325	P=0.070	P=0.175	P=0.175
MAX-ISO-POLY-3	P=0.029*	P<0.001**	P=0.188	P=0.020*	P=0.079	P=0.079

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lymph Node, Mandibular						
Hyperplasia Lymphoid						
LESION RATES						
OVERALL (a)	3/10 (30%)	0/10 (0%)	2/10 (20%)	0/10 (0%)	1/10 (10%)	2/10 (20%)
POLY-3 RATE (b)	3/10.00	0/10.00	2/10.00	0/10.00	1/10.00	2/10.00
POLY-3 PERCENT (g)	30%	0%	20%	0%	10%	20%
TERMINAL (d)	3/10 (30%)	0/10 (0%)	2/10 (20%)	0/10 (0%)	1/10 (10%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	93 (T)	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.537	P=0.095N	P=0.500N	P=0.095N	P=0.292N	P=0.500N
POLY 1.5	P=0.537	P=0.095N	P=0.500N	P=0.095N	P=0.292N	P=0.500N
POLY 6	P=0.537	P=0.095N	P=0.500N	P=0.095N	P=0.292N	P=0.500N
COCH-ARM / FISHERS	P=0.537	P=0.105N	P=0.500N	P=0.105N	P=0.291N	P=0.500N
MAX-ISO-POLY-3	P=0.092N	P=0.025N*	P=0.310N	P=0.025N*	P=0.136N	P=0.310N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lymph Node, Mesenteric **Infiltration Cellular Histiocyte**						
LESION RATES						
OVERALL (a)	0/10 (0%)	2/10 (20%)	6/10 (60%)	7/10 (70%)	7/10 (70%)	7/10 (70%)
POLY-3 RATE (b)	0/10.00	2/10.00	6/10.00	7/10.00	7/10.00	7/10.00
POLY-3 PERCENT (g)	0%	20%	60%	70%	70%	70%
TERMINAL (d)	0/10 (0%)	2/10 (20%)	6/10 (60%)	7/10 (70%)	7/10 (70%)	7/10 (70%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.227	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.227	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.227	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.004**	P=0.237	P=0.005**	P=0.002**	P=0.002**	P=0.002**
MAX-ISO-POLY-3	P<0.001**	P=0.066	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose						
Inflammation						
LESION RATES						
OVERALL (a)	2/10 (20%)	3/10 (30%)	1/10 (10%)	2/10 (20%)	3/10 (30%)	5/10 (50%)
POLY-3 RATE (b)	2/10.00	3/10.00	1/10.00	2/10.00	3/10.00	5/10.00
POLY-3 PERCENT (g)	20%	30%	10%	20%	30%	50%
TERMINAL (d)	2/10 (20%)	3/10 (30%)	1/10 (10%)	2/10 (20%)	3/10 (30%)	5/10 (50%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.055	P=0.500	P=0.500N	P=0.702	P=0.500	P=0.174
POLY 1.5	P=0.055	P=0.500	P=0.500N	P=0.702	P=0.500	P=0.174
POLY 6	P=0.055	P=0.500	P=0.500N	P=0.702	P=0.500	P=0.174
COCH-ARM / FISHERS	P=0.053	P=0.500	P=0.500N	P=0.709N	P=0.500	P=0.175
MAX-ISO-POLY-3	P=0.055	P=0.310	P=0.274N	P=1.000	P=0.310	P=0.079

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Lamina Propria						
Pigmentation Histiocyte						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
POLY 1.5	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
POLY 6	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	(e)	(e)	P=0.237
MAX-ISO-POLY-3	P=0.005**	(e)	(e)	(e)	(e)	P=0.066

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Nasopharyngeal Duct Degeneration						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)	3/10 (30%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	3/10.00	3/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	30%	30%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)	3/10 (30%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P=0.095	P=0.095
POLY 1.5	P<0.001**	(e)	(e)	(e)	P=0.095	P=0.095
POLY 6	P<0.001**	(e)	(e)	(e)	P=0.095	P=0.095
COCH-ARM / FISHERS	P=0.002**	(e)	(e)	(e)	P=0.105	P=0.105
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P=0.025*	P=0.025*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Nasopharyngeal Duct Inflammation						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	3/10 (30%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	2/10.00	3/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	20%	30%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	3/10 (30%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P=0.227	P=0.095
POLY 1.5	P<0.001**	(e)	(e)	(e)	P=0.227	P=0.095
POLY 6	P<0.001**	(e)	(e)	(e)	P=0.227	P=0.095
COCH-ARM / FISHERS	P=0.002**	(e)	(e)	(e)	P=0.237	P=0.105
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P=0.066	P=0.025*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Nerve Atrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	5/10 (50%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	5/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	50%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	5/10 (50%)	10/10 (100%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P=0.008**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P=0.008**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	P=0.008**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.016*	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P<0.001**	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium						
Atrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	2/10 (20%)	1/10 (10%)	3/10 (30%)	9/10 (90%)
POLY-3 RATE (b)	0/10.00	0/10.00	2/10.00	1/10.00	3/10.00	9/10.00
POLY-3 PERCENT (g)	0%	0%	20%	10%	30%	90%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	2/10 (20%)	1/10 (10%)	3/10 (30%)	9/10 (90%)
FIRST INCIDENCE	---	---	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.227	P=0.500	P=0.095	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.227	P=0.500	P=0.095	P<0.001**
POLY 6	P<0.001**	(e)	P=0.227	P=0.500	P=0.095	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.237	P=0.500	P=0.105	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.066	P=0.158	P=0.025*	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium Metaplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	6/10 (60%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	0/10.00	6/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	10%	0%	60%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	6/10 (60%)	10/10 (100%)
FIRST INCIDENCE	---	---	93 (T)	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.500	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.500	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.500	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.500	(e)	P=0.005**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.158	(e)	P<0.001**	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium						
Necrosis						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	3/10 (30%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	1/10.00	3/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	10%	30%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	3/10 (30%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P=0.500	P=0.095
POLY 1.5	P<0.001**	(e)	(e)	(e)	P=0.500	P=0.095
POLY 6	P<0.001**	(e)	(e)	(e)	P=0.500	P=0.095
COCH-ARM / FISHERS	P=0.002**	(e)	(e)	(e)	P=0.500	P=0.105
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P=0.158	P=0.025*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium Pigmentation						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	4/10 (40%)	5/10 (50%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	4/10.00	5/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	40%	50%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	4/10 (40%)	5/10 (50%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P=0.033*	P=0.008**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P=0.033*	P=0.008**
POLY 6	P<0.001**	(e)	(e)	(e)	P=0.033*	P=0.008**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.043*	P=0.016*
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P=0.007**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium, Glands						
Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)	7/10 (70%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	3/10.00	7/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	30%	70%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)	7/10 (70%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P=0.095	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P=0.095	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	P=0.095	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.105	P=0.002**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P=0.025*	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Respiratory Epithelium Hyperplasia						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	4/10 (40%)
POLY-3 RATE (b)	1/10.00	0/10.00	0/10.00	0/10.00	2/10.00	4/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	20%	40%
TERMINAL (d)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	4/10 (40%)
FIRST INCIDENCE	93 (T)	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.500N	P=0.500N	P=0.500N	P=0.500	P=0.148
POLY 1.5	P<0.001**	P=0.500N	P=0.500N	P=0.500N	P=0.500	P=0.148
POLY 6	P<0.001**	P=0.500N	P=0.500N	P=0.500N	P=0.500	P=0.148
COCH-ARM / FISHERS	P=0.002**	P=0.500N	P=0.500N	P=0.500N	P=0.500	P=0.152
MAX-ISO-POLY-3	P<0.001**	P=0.158N	P=0.158N	P=0.158N	P=0.274	P=0.058

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Preputial Gland Inflammation						
LESION RATES						
OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	9/10 (90%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	9/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	90%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	9/10 (90%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.760
COCH-ARM / FISHERS	P=0.645	(e)	(e)	(e)	(e)	P=0.763N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Testes: Seminiferous Tubule Degeneration						
LESION RATES						
OVERALL (a)	3/10 (30%)	1/10 (10%)	2/10 (20%)	3/10 (30%)	3/10 (30%)	7/10 (70%)
POLY-3 RATE (b)	3/10.00	1/10.00	2/10.00	3/10.00	3/10.00	7/10.00
POLY-3 PERCENT (g)	30%	10%	20%	30%	30%	70%
TERMINAL (d)	3/10 (30%)	1/10 (10%)	2/10 (20%)	3/10 (30%)	3/10 (30%)	7/10 (70%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.004**	P=0.292N	P=0.500N	P=0.678	P=0.678	P=0.082
POLY 1.5	P=0.004**	P=0.292N	P=0.500N	P=0.678	P=0.678	P=0.082
POLY 6	P=0.004**	P=0.292N	P=0.500N	P=0.678	P=0.678	P=0.082
COCH-ARM / FISHERS	P=0.005**	P=0.291N	P=0.500N	P=0.686N	P=0.686N	P=0.089
MAX-ISO-POLY-3	P=0.004**	P=0.136N	P=0.310N	P=1.000	P=1.000	P=0.032*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Thymus						
Atrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	5/8 (63%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	1/10.00	0/10.00	5/8.00
POLY-3 PERCENT (g)	0%	0%	0%	10%	0%	62.5%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	5/8 (63%)
FIRST INCIDENCE	---	---	---	93 (T)	---	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	P=0.500	(e)	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	P=0.500	(e)	P<0.001**
POLY 6	P<0.001**	(e)	(e)	P=0.500	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P=0.500	(e)	P=0.007**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	P=0.158	(e)	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Adrenal Cortex						
Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/1 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.11	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.289	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Clitoral Gland Inflammation						
LESION RATES						
OVERALL (a)	5/10 (50%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	5/10.00	0/0.00	1/1.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	50%	0%	100%	0%	0%	20%
TERMINAL (d)	5/10 (50%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	45	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.536	(e)	(e)	P=0.174N
POLY 1.5	(e)	(e)	P=0.536	(e)	(e)	P=0.174N
POLY 6	(e)	(e)	P=0.536	(e)	(e)	P=0.174N
COCH-ARM / FISHERS	P=0.089N	(e)	P=0.545	(e)	(e)	P=0.175N
MAX-ISO-POLY-3	(e)	(e)	P=0.251	(e)	(e)	P=0.079N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Heart **Cardiomyopathy**						
LESION RATES						
OVERALL (a)	9/10 (90%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)	6/10 (60%)
POLY-3 RATE (b)	9/10.00	0/0.00	1/1.00	0/0.00	0/0.00	6/10.00
POLY-3 PERCENT (g)	90%	0%	100%	0%	0%	60%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/10 (60%)
FIRST INCIDENCE	93 (T)	---	45	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.913	(e)	(e)	P=0.148N
POLY 1.5	(e)	(e)	P=0.913	(e)	(e)	P=0.148N
POLY 6	(e)	(e)	P=0.913	(e)	(e)	P=0.148N
COCH-ARM / FISHERS	P=0.083N	(e)	P=0.909	(e)	(e)	P=0.152N
MAX-ISO-POLY-3	(e)	(e)	P=0.409	(e)	(e)	P=0.058N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Kidney **Mineralization**						
LESION RATES						
OVERALL (a)	5/10 (50%)	0/0 (0%)	0/1 (0%)	0/0 (0%)	0/0 (0%)	5/10 (50%)
POLY-3 RATE (b)	5/10.00	0/0.00	0/0.11	0/0.00	0/0.00	5/10.00
POLY-3 PERCENT (g)	50%	0%	0%	0%	0%	50%
TERMINAL (d)	5/10 (50%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	5/10 (50%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.803N	(e)	(e)	P=0.664
POLY 1.5	(e)	(e)	P=0.745N	(e)	(e)	P=0.664
POLY 6	(e)	(e)	P=0.826N	(e)	(e)	P=0.664
COCH-ARM / FISHERS	P=0.525	(e)	P=0.545N	(e)	(e)	P=0.672N
MAX-ISO-POLY-3	(e)	(e)	P=0.468N	(e)	(e)	P=1.000

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Kidney						
Nephropathy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/1 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.11	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.289	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver						
Hepatodiaphragmatic Nodule						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/10 (0%)	1/10 (10%)	2/10 (20%)	1/10 (10%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/10.00	1/9.11	2/10.00	1/10.00	2/10.00
POLY-3 PERCENT (g)	10%	0%	11%	20%	10%	20%
TERMINAL (d)	1/10 (10%)	0/10 (0%)	1/9 (11%)	2/10 (20%)	1/10 (10%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.249	P=0.500N	P=0.740	P=0.500	P=0.760	P=0.500
POLY 1.5	P=0.247	P=0.500N	P=0.745	P=0.500	P=0.760	P=0.500
POLY 6	P=0.250	P=0.500N	P=0.737	P=0.500	P=0.760	P=0.500
COCH-ARM / FISHERS	P=0.236	P=0.500N	P=0.763N	P=0.500	P=0.763N	P=0.500
MAX-ISO-POLY-3	P=0.154	P=0.158N	P=0.473	P=0.274	P=1.000	P=0.274

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver						
Infiltration Cellular Mononuclear Cell						
LESION RATES						
OVERALL (a)	9/10 (90%)	8/10 (80%)	6/10 (60%)	7/10 (70%)	8/10 (80%)	7/10 (70%)
POLY-3 RATE (b)	9/10.00	8/10.00	6/10.00	7/10.00	8/10.00	7/10.00
POLY-3 PERCENT (g)	90%	80%	60%	70%	80%	70%
TERMINAL (d)	9/10 (90%)	8/10 (80%)	5/9 (56%)	7/10 (70%)	8/10 (80%)	7/10 (70%)
FIRST INCIDENCE	93 (T)	93 (T)	45	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.406N	P=0.500N	P=0.148N	P=0.292N	P=0.500N	P=0.292N
POLY 1.5	P=0.406N	P=0.500N	P=0.148N	P=0.292N	P=0.500N	P=0.292N
POLY 6	P=0.406N	P=0.500N	P=0.148N	P=0.292N	P=0.500N	P=0.292N
COCH-ARM / FISHERS	P=0.403N	P=0.500N	P=0.152N	P=0.291N	P=0.500N	P=0.291N
MAX-ISO-POLY-3	P=0.157N	P=0.274N	P=0.058N	P=0.136N	P=0.274N	P=0.136N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver						
Mitosis						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
POLY 1.5	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
POLY 6	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	(e)	(e)	P=0.237
MAX-ISO-POLY-3	P=0.005**	(e)	(e)	(e)	(e)	P=0.066

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver Pigmentation						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
POLY 1.5	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
POLY 6	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	(e)	(e)	P=0.237
MAX-ISO-POLY-3	P=0.005**	(e)	(e)	(e)	(e)	P=0.066

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver: Bile Duct Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	3/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	30%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.105
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	P=0.025*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver: Oval Cell Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	3/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	30%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.105
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	P=0.025*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Liver: Periportal Hypertrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
POLY 1.5	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
POLY 6	P=0.008**	(e)	(e)	(e)	(e)	P=0.227
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	(e)	(e)	P=0.237
MAX-ISO-POLY-3	P=0.005**	(e)	(e)	(e)	(e)	P=0.066

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lung						
Hemorrhage						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/1 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.11	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	20%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.941N	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	P=0.936N	(e)	(e)	P=0.500
POLY 6	(e)	(e)	P=0.943N	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.351	(e)	P=0.909N	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	P=0.488N	(e)	(e)	P=0.274

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lung **Inflammation**						
LESION RATES						
OVERALL (a)	8/10 (80%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)	9/10 (90%)
POLY-3 RATE (b)	8/10.00	0/0.00	1/1.00	0/0.00	0/0.00	9/10.00
POLY-3 PERCENT (g)	80%	0%	100%	0%	0%	90%
TERMINAL (d)	8/10 (80%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	9/10 (90%)
FIRST INCIDENCE	93 (T)	---	45	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.786	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	P=0.786	(e)	(e)	P=0.500
POLY 6	(e)	(e)	P=0.786	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.402	(e)	P=0.818	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	P=0.366	(e)	(e)	P=0.274

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lymph Node, Mandibular						
Hyperplasia						
LESION RATES						
OVERALL (a)	4/10 (40%)	5/10 (50%)	7/10 (70%)	7/10 (70%)	7/10 (70%)	8/10 (80%)
POLY-3 RATE (b)	4/10.00	5/10.00	7/10.00	7/10.00	7/10.00	8/10.00
POLY-3 PERCENT (g)	40%	50%	70%	70%	70%	80%
TERMINAL (d)	4/10 (40%)	5/10 (50%)	6/9 (67%)	7/10 (70%)	7/10 (70%)	8/10 (80%)
FIRST INCIDENCE	93 (T)	93 (T)	45	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.069	P=0.500	P=0.186	P=0.186	P=0.186	P=0.077
POLY 1.5	P=0.069	P=0.500	P=0.186	P=0.186	P=0.186	P=0.077
POLY 6	P=0.069	P=0.500	P=0.186	P=0.186	P=0.186	P=0.077
COCH-ARM / FISHERS	P=0.067	P=0.500	P=0.185	P=0.185	P=0.185	P=0.085
MAX-ISO-POLY-3	P=0.033*	P=0.332	P=0.089	P=0.089	P=0.089	P=0.029*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lymph Node, Mandibular **Hyperplasia Lymphoid**						
LESION RATES						
OVERALL (a)	3/10 (30%)	4/10 (40%)	1/10 (10%)	1/10 (10%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	3/10.00	4/10.00	1/9.11	1/10.00	0/10.00	2/10.00
POLY-3 PERCENT (g)	30%	40%	11%	10%	0%	20%
TERMINAL (d)	3/10 (30%)	4/10 (40%)	1/9 (11%)	1/10 (10%)	0/10 (0%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	---	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.237N	P=0.500	P=0.328N	P=0.292N	P=0.095N	P=0.500N
POLY 1.5	P=0.241N	P=0.500	P=0.318N	P=0.292N	P=0.095N	P=0.500N
POLY 6	P=0.236N	P=0.500	P=0.332N	P=0.292N	P=0.095N	P=0.500N
COCH-ARM / FISHERS	P=0.255N	P=0.500	P=0.291N	P=0.291N	P=0.105N	P=0.500N
MAX-ISO-POLY-3	P=0.071N	P=0.325	P=0.171N	P=0.136N	P=0.025N*	P=0.310N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Lymph Node, Mesenteric **Infiltration Cellular Histiocyte**						
LESION RATES						
OVERALL (a)	8/10 (80%)	10/10 (100%)	9/10 (90%)	7/10 (70%)	7/10 (70%)	6/10 (60%)
POLY-3 RATE (b)	8/10.00	10/10.00	9/10.00	7/10.00	7/10.00	6/10.00
POLY-3 PERCENT (g)	80%	100%	90%	70%	70%	60%
TERMINAL (d)	8/10 (80%)	10/10 (100%)	8/9 (89%)	7/10 (70%)	7/10 (70%)	6/10 (60%)
FIRST INCIDENCE	93 (T)	93 (T)	45	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.039N*	P=0.227	P=0.500	P=0.500N	P=0.500N	P=0.318N
POLY 1.5	P=0.039N*	P=0.227	P=0.500	P=0.500N	P=0.500N	P=0.318N
POLY 6	P=0.039N*	P=0.227	P=0.500	P=0.500N	P=0.500N	P=0.318N
COCH-ARM / FISHERS	P=0.039N*	P=0.237	P=0.500	P=0.500N	P=0.500N	P=0.314N
MAX-ISO-POLY-3	P=0.039N*	P=0.066	P=0.274	P=0.310N	P=0.310N	P=0.172N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose						
Inflammation						
LESION RATES						
OVERALL (a)	2/10 (20%)	1/10 (10%)	1/10 (10%)	4/10 (40%)	10/10 (100%)	8/10 (80%)
POLY-3 RATE (b)	2/10.00	1/10.00	1/9.11	4/10.00	10/10.00	8/10.00
POLY-3 PERCENT (g)	20%	10%	11%	40%	100%	80%
TERMINAL (d)	2/10 (20%)	1/10 (10%)	1/9 (11%)	4/10 (40%)	10/10 (100%)	8/10 (80%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.500N	P=0.533N	P=0.318	P<0.001**	P=0.004**
POLY 1.5	P<0.001**	P=0.500N	P=0.525N	P=0.318	P<0.001**	P=0.004**
POLY 6	P<0.001**	P=0.500N	P=0.537N	P=0.318	P<0.001**	P=0.004**
COCH-ARM / FISHERS	P<0.001**	P=0.500N	P=0.500N	P=0.314	P<0.001**	P=0.012*
MAX-ISO-POLY-3	P<0.001**	P=0.274N	P=0.309N	P=0.172	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Lamina Propria						
Pigmentation Histiocyte						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.109	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	P=0.108	(e)	(e)	(e)	(e)	P=0.500
POLY 6	P=0.109	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.105	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.041*	(e)	(e)	(e)	(e)	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Nasopharyngeal Duct Degeneration						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	2/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	20%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	2/10 (20%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	93 (T)	---
STATISTICAL TESTS						
POLY 3	P=0.419	(e)	(e)	(e)	P=0.227	(e)
POLY 1.5	P=0.417	(e)	(e)	(e)	P=0.227	(e)
POLY 6	P=0.420	(e)	(e)	(e)	P=0.227	(e)
COCH-ARM / FISHERS	P=0.414	(e)	(e)	(e)	P=0.237	(e)
MAX-ISO-POLY-3	P=0.096	(e)	(e)	(e)	P=0.066	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Nasopharyngeal Duct Inflammation						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Nerve Atrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	4/10 (40%)	5/10 (50%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	1/10.00	4/10.00	5/10.00
POLY-3 PERCENT (g)	0%	0%	0%	10%	40%	50%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	1/10 (10%)	4/10 (40%)	5/10 (50%)
FIRST INCIDENCE	---	---	---	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	P=0.500	P=0.033*	P=0.008**
POLY 1.5	P<0.001**	(e)	(e)	P=0.500	P=0.033*	P=0.008**
POLY 6	P<0.001**	(e)	(e)	P=0.500	P=0.033*	P=0.008**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P=0.500	P=0.043*	P=0.016*
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	P=0.158	P=0.007**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium Atrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	7/10 (70%)
POLY-3 RATE (b)	0/10.00	1/10.00	1/9.11	0/10.00	0/10.00	7/10.00
POLY-3 PERCENT (g)	0%	10%	11%	0%	0%	70%
TERMINAL (d)	0/10 (0%)	1/10 (10%)	1/9 (11%)	0/10 (0%)	0/10 (0%)	7/10 (70%)
FIRST INCIDENCE	---	93 (T)	93 (T)	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.500	P=0.481	(e)	(e)	P<0.001**
POLY 1.5	P<0.001**	P=0.500	P=0.486	(e)	(e)	P<0.001**
POLY 6	P<0.001**	P=0.500	P=0.479	(e)	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500	P=0.500	(e)	(e)	P=0.002**
MAX-ISO-POLY-3	P<0.001**	P=0.158	P=0.157	(e)	(e)	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium Metaplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	5/10 (50%)	4/10 (40%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	5/10.00	4/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	50%	40%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	5/10 (50%)	4/10 (40%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P=0.008**	P=0.033*
POLY 1.5	P<0.001**	(e)	(e)	(e)	P=0.008**	P=0.033*
POLY 6	P<0.001**	(e)	(e)	(e)	P=0.008**	P=0.033*
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.016*	P=0.043*
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P<0.001**	P=0.007**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium						
Necrosis						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium **Pigmentation**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	3/10 (30%)	5/10 (50%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	2/10.00	3/10.00	5/10.00
POLY-3 PERCENT (g)	0%	0%	0%	20%	30%	50%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	2/10 (20%)	3/10 (30%)	5/10 (50%)
FIRST INCIDENCE	---	---	---	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	P=0.227	P=0.095	P=0.008**
POLY 1.5	P<0.001**	(e)	(e)	P=0.227	P=0.095	P=0.008**
POLY 6	P<0.001**	(e)	(e)	P=0.227	P=0.095	P=0.008**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P=0.237	P=0.105	P=0.016*
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	P=0.066	P=0.025*	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Olfactory Epithelium, Glands						
Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	1/10 (10%)	4/10 (40%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	2/10.00	1/10.00	4/10.00
POLY-3 PERCENT (g)	0%	0%	0%	20%	10%	40%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	2/10 (20%)	1/10 (10%)	4/10 (40%)
FIRST INCIDENCE	---	---	---	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	P=0.227	P=0.500	P=0.033*
POLY 1.5	P<0.001**	(e)	(e)	P=0.227	P=0.500	P=0.033*
POLY 6	P<0.001**	(e)	(e)	P=0.227	P=0.500	P=0.033*
COCH-ARM / FISHERS	P=0.002**	(e)	(e)	P=0.237	P=0.500	P=0.043*
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	P=0.066	P=0.158	P=0.007**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose: Respiratory Epithelium Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	1/10.00	1/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	10%	10%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	93 (T)	93 (T)	---
STATISTICAL TESTS						
POLY 3	P=0.628	(e)	(e)	P=0.500	P=0.500	(e)
POLY 1.5	P=0.625	(e)	(e)	P=0.500	P=0.500	(e)
POLY 6	P=0.629	(e)	(e)	P=0.500	P=0.500	(e)
COCH-ARM / FISHERS	P=0.620	(e)	(e)	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.206	(e)	(e)	P=0.158	P=0.158	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Females

DOSE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Thymus						
Atrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	6/10 (60%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.11	0/10.00	0/10.00	6/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	60%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	6/10 (60%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.005**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(e)	Value of Statistic cannot be computed.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
(g)	Poly-3 adjusted lifetime tumor incidence.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***